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Reactive oxygen species reprogram
macrophages to suppress antitumor immune
response through the exosomal miR-155-5p/
PD-L1 pathway
Xiang Li1,2, Shaomin Wang1, Wei Mu3, Jennifer Barry1, Anna Han4, Richard L. Carpenter5, Bing‑Hua Jiang1,
Stephen C. Peiper1, Mỹ G. Mahoney6, Andrew E. Aplin4, Hong Ren7* and Jun He1*

Abstract
Background: Cancer cells have an imbalance in oxidation-reduction (redox) homeostasis. Understanding the precise
mechanisms and the impact of the altered redox microenvironment on the immunologic reaction to tumors is
limited.
Methods: We isolated exosomes from ovarian cancer cells through ultracentrifuge and characterized by Westernblots and Nanoparticle Tracking Analysis. 2D, 3D-coculture tumor model, and 3D live cell imaging were used to study
the interactions between tumor cells, macrophages and CD3 T cells in vitro. The role of exosomal miR-155-5p in
tumor growth was evaluated in xenograft nude mice models and immune-competent mice models. Flow cytometry
and flow sorting were used to determine the expression levels of miR-155-5p and PD-L1 in ascites and splenic mac‑
rophages, and the percentages of CD3 T cells subpopulations.
Results: The elevation of reactive oxygen species (ROS) greatly downregulated exosomal miR-155-5p expression
in tumor cells. Neutralization of ROS with N-acetyl-L-cysteine (NAC) increased the levels of miR-155-5p in tumor
exosomes that were taken up by macrophages, leading to reduction of macrophage migration and tumor spheroid
infiltration. We further found that programmed death ligand 1 (PD-L1) is a functional target of miR-155-5p. Co-culture
of macrophages pre-treated with NAC-derived tumor exosomes or exosomal miR-155-5p with T-lymphocytes leading
to an increased percentage of CD8+ T-lymphocyte and a decreased CD3+ T cell apoptosis through PD-L1 downregu‑
lation. Tumor growth in nude mice was delayed by treatment with NAC-derived tumor exosomes. Delivery of tumor
exo-miR-155-5p in immune-intact mice suppressed ovarian cancer progression and macrophage infiltration, and acti‑
vated CD8+ T cell function. It is of note that exo-miR-155-5p inhibited tumor growth more potently than the PD-L1
antibody, suggesting that in addition to PD-L1, other pathways may also be targeted by this approach.
Conclusions: Our findings demonstrate a novel mechanism, ROS-induced down-regulation of miR-155-5p, by which
tumors modulate the microenvironment that favors tumor growth. Understanding of the negative impact of ROS on
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the tumor immune response will improve current therapeutic strategies. Targeting miR-155-5p can be an alternative
approach to prevent formation of an immunosuppressive TME through downregulation of PD-L1 and other immuno‑
suppressive factors.
Keywords: Reactive oxygen species, Tumor immune response, Ovarian cancer, Tumor-associated macrophages,
Tumor exosomes, miR-155-5p, PD-L1

Background
Epithelial ovarian cancer (EOC) is the most lethal
gynecological cancer in the United States, with an estimated 22,530 new cases diagnosed and 13,980 deaths in
2019 [1, 2]. Despite the standard first-line chemotherapy
following cytoreductive surgery, the mortality rate has
not improved in the era of targeted-therapy; the 5-year
survival rate is around 39% for all EOC and 30% for in
patients at stage III and IV [1]. More than half of cases
are diagnosed at advanced stages with extensive intraperitoneal disseminated metastasis and chemotherapeutic resistance [3, 4]. Growing evidence suggests that
the peritoneal tumor microenvironment (TME) plays
an essential role in ovarian cancer progression, metastasis, and the development of drug resistance [5]. During
metastasis of ovarian cancer, the intraperitoneal tumor
microenvironment forms an immunosuppressive milieu
with accumulated ascites that contain a large number of
tumor spheroids and various stromal and immune cells,
such as macrophages and lymphocytes, as well as soluble
pro-tumor mediators [6]. The macrophages that infiltrate
into the tumor microenvironment are defined as tumorassociated macrophage (TAMs), which generally display
an anti-inflammatory and pro-tumor M2-like phenotype,
and thus play an important role in facilitating the peritoneal dissemination of ovarian cancer cells [7]. Increased
recruitment of TAMs into tumor spheroids floating in
the ascites has been positively correlated with poor outcomes in patients with advanced ovarian cancer [6]. It
remains unclear how ovarian tumor cells evade immune
surveillance, a key obstacle to develop effective immunotherapy for ovarian cancer treatment.
Exosomes are nanometer-sized membrane encapsulated vesicles released by all cell types to convey information to neighboring or distant cells by transporting
cytosolic biomolecules, such as proteins, DNA, mRNAs,
and miRNAs, and thus influence recipient cells [8, 9].
Among all of the cell types, tumor cells secrete at least
10-fold more exosomes than other cells [10]. Exosomes
generated by tumors carry cargos that partially mimic
parent cell content, and thereby they reprogram recipient
cells into active contributors to angiogenesis, metastasis,
and immunosuppression [11]. Tumor cells generate distinct exosomes that are regulated by external signals, particularly from oxidative stress [12]. We previously showed

that ovarian cancer cells produce excessive reactive oxygen species (ROS) with NOX4 being the major contributor [13]. ROS can regulate the biogenesis and expression
of miRNAs, which may in turn affect redox signaling
pathways and thus promote tumorigenesis and progression [14, 15]. However, it has yet to be determined how
these miRNAs convey the ROS signal to downstream
effectors leading to alterations in the extracellular milieu
that creates a redox microenvironment. The current
study aimed to investigate whether and how ROS influence the TME to promote ovarian cancer development
through tumor exosomal miRNAs. We found that ROS
decreased the amount of tumor exo-miR-155 that was
taken up by macrophages, resulting in enhanced macrophage infiltration and T cell inactivation characterized
by upregulation of programmed death ligand 1 (PD-L1).
Targeting ROS/miR-155-5p is a promising strategy to
prevent the formation of the suppressive tumor microenvironment in ovarian cancer.

Methods
Cell lines, reagents, and antibodies

Human ovarian cancer cell line A2780, Ovcar-3, and
SKOV-3, murine ovarian cancer cell line ID8, and human
peripheral blood monocytes THP-1 were purchased from
the American Type Culture Collection (ATCC). Peripheral blood mononuclear cells (PBMC) were purchased
from Stemcell Technologies. All cell lines were cultured
in RPMI 1640 or in Dulbecco’s modified Eagle’s (DMEM)
media supplemented with 10% FBS. All cell lines did not
have mycoplasma contamination determined by RT-PCR.
N-acetyl-L-cysteine (NAC) was purchased from Selleckchem, and phorbol 12-myristate 13-acetate (PMA),
catalase-PEG, and rotenone were from Sigma Aldrich.
The sources of antibodies used in immunoblotting, flow
cytometry, and IHC were shown in Suppl. Table 2.
Exosomes purification from cell culture supernatant,
ascites, and serum

Exosomes from cell culture medium were isolated by
ultracentrifugation. Ovarian cancer cells were grown in
T75 flasks until they reached to 70% confluency, and then
were rinsed with PBS and then replaced with serum-free
medium for 48 h. The supernatant was collected and centrifuged at 2000×g for 30 min to discard cellular debris.
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Next, the collected medium were centrifuged at 12000×g
for 30 min at 4 °C followed by filtration through 0.22-μm
pore filters (Steriflip, Millipore) to remove larger extracellular vesicles. The supernatant were then and ultracentrifuged at 110,000×g for 2 h at 4 °C (Beckman Coulter, Ti45
rotor). The exosomes pellets were re-suspended in 10 ml
PBS, and loaded over 10 ml of 40% sucrose solution, and
was ultracentrifuged at 110,000×g for 90 min. The lower
sucrose layer, which contained the exosomes was diluted
with PBS and ultracentrifuged at 110,000×g for 90 min.
The pellet was resuspended in 100 μl PBS and stored in
− 80 °C. Exosomes from ascites in mice were isolated
using the same method except for erythrocytes lysis with
ACK lysis buffer (Thermo Fisher Scientific) after the initial centrifuge at 1500×g for 15 min to remove debris.
Exosomes from the serum in mice were isolated using
Exosome Isolation Reagent (Invitrogen, Thermo Fisher
Scientific). The serum exosomes were characterized by
NTA.
Nanoparticle tracking analysis (NTA)

NTA was performed using a NanoSight NS300 instrument according to the manufacturer’s instructions. Isolated exosome samples were diluted with PBS at 1:100
before analysis. The settings after NTA collection were
optimized and remained constant between samples.
Three videos of 60 s length were recorded for each sample
and analyzed to give estimates of mean size and number
of particles.
Nanostring nCounter miRNA expression assay

All samples were prepared and processed according to
NanoString nCounter Expression CodeSet Design Manual. 100 ng of exosomal RNAs were used as input for
Nanostring nCounter miRNA sample preparation. Raw
data were normalized to the top 100 miRs using nSolver
analysis 2.5 software (Nanostring). Expression heatmaps
were generated with the R package pheatmap.
Fluorescence in situ hybridization

In situ hybridization was performed using double digoxigenin (DIG)-labeled miRCURY LNA miRNA detection probe hsa-miR-155-5p (Advanced Cell Diagnostics,
CA, USA) in human ovarian carcinoma tissue microarray (US Biomax, MD, USA). The TMA sections contain
160 cases of ovarian cancer tissue sections and 40 cases
of normal human ovary tissue sections. The experiments were performed according to the miRNAscope LS
Automated Assay (ACD, CA, USA) protocol. The signal
was detected with miRNAscope™ LS Reagent Kit - RED
(ACD, CA, USA). Slow Fade Gold anti-fade reagent with
DAPI (Life Technologies) was employed as the mounting
medium. The positive and negative control of the method
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was verified employing miRNAscope LS Positive Control Probe (ACD, CA, USA) and miRNAscope LS Negative Control Probe (ACD, CA, USA), respectively. Bright
field pictures were scanned by Pannoramic slide scanner
(3DHISTECH) and converted to fluorescence signal with
Caseviewer 2.2 software. Pictures were taken by ImagePro Plus 6.0 software. Slides were analyzed with Quant
Center 2.1 (Thermo Fisher Scientific) and Graphpad
Prism software (La Jolla, CA, USA).
RT‑qPCR

Total RNAs were extracted using Trizol (Thermo Fisher
Scientific). The cDNA synthesis was performed using
oligo (dT)18 primers and M-MLV reverse transcriptase.
The 100 ng of RT product was used for PCR reaction
using Power SYBR Green PCR Master Mix (Thermo
Fisher Sci). The primer sequences are listed in Supplementary Table 1.
Two-step Taqman-qPCR analysis was performed to
assess miRNA levels using Taqman miRNA reverse transcription kit and Taqman universal PCR master mix
(Thermo Fisher Sci) in accordance with manufacturer’s
instructions.
Fluorescent labeling of exosomes with DiR

Exosomes were fluorescently labeled using lipophilic
carbocyanine DiR dye (Thermo Fisher Scientific). In
brief, 5 μl of DiR (200 μg/ml) in ethanol was mixed with
200 μg exosomes in 100 μl PBS for 1 h. The unincorportated DiR was removed by a Sepharose CL-4B column
(Sigma-Aldrich).
Dual luciferase reporter assay

THP-1 cells were seeded in 12-well plates at a number of
5 × 105 and were co-transfected with PD-L1-WT 3′-UTR
reporter plasmids (Addgene) and miR-cont, miR-155-5p
mimics, miR-152-3p mimics, or miR-137 mimics, using
jetPRIME® reagent. The transfected cells were harvested 48 h post-transfection using Passive Lysis Buffer
(Promega, US), and firefly and Renilla luciferase activities were measured in cell lysates using Dual-Luciferase
Reporter Assay System (Promega).
3D‑coculture tumor model and 3D live cell imaging

A2780-miR-con and A2780-miR-155 cells were seeded
onto 1% agarose (Sigma-Aldrich) substrate in the cover
glass bottom of 48-well plates (MatTek, MA, USA) at
1 × 104 cells/well. After 4 days of formation of tumor
spheroids, macrophages were added and allowed to coculture with tumor spheroids for an additional 4 days.
The diameters of spheroids were measured at 3 d, 7 d, 10
d and 12 d, respectively. For the 3D live cell imaging, the
cells were stained with Cell tracker green (Thermo Fisher
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Scientific) before seeding onto 1% agarose concave surface for spheroid formation. The infiltrated macrophages
were stained by eFluor670 (Thermo Fisher Scientific)
before adding into tumor spheroids. The pictures of the
3D co-culture were taken by an A1R+ Nikon confocal microscope for 3D live cell imaging. The number
of A2780 and infiltrated macrophages were presented
as accumulative average intensity of fluorescence. Z
stack-overlay video was taken by A1R+ Nikon confocal
microscope.
Flow cytometry and fluorescence‑activated cell sorting
(FACS)

For cultured cells or 3D co-culture cells, single-cell suspensions were incubated with 2% human Fc Receptor block (eBioscience, Frankfurt, Germany) in PBS for
20 min on ice. After washing with PBS, cells were stained
with conjugated antibodies for 30 min at room temperature in the dark. For tumors, spleen, and ascites from
mouse models, single-cell suspensions were prepared
by tissue extraction, mashing, digestion with Liberase
DL, TL (Roche, USA) and DNase І (Sigma-Aldrich, Germany). The erythrocytes were lysed with ACK lysis buffer
(Gibco, Thermo Fisher Scientific), filtered by 40 μm pore
size filter (Corning, NY, USA), incubated with 2% human
Fc receptor blocking (eBioscience, Frankfurt, Germany),
and stained with conjugated antibodies. Isotype IgG
control was used in each experiment as reference. Flow
cytometry was performed using BD Celesta, BD LSRII, or
BD Fortessa (BD Bioscience, US). FACS was performed
using BD Aria II or BD Melody (BD Bioscience, US). Data
were analyzed using FlowJo software (Tree Star Inc., CA,
USA).
Human CD3+ T cell preparation

The human PBMCs were purchased from Stemcell Technologies (Cambridge, MA). CD3+ T cells were separated
using CD3 microbeads (Miltenyi Biotec, USA) together
with MACS columns and separators according to the
manufacturer’s instructions. For stimulation of T cells,
24-well plates were coated with 10 μg/ml CD3 purified
antibody. After washing with PBS twice, isolated CD3+ T
cell were plated in CD3-coated plate in culture medium,
and stimulated with CD28 purified antibody in the presence of 30 U/ml recombinant human IL-2 (Peprotech,
USA).
In vivo tumor models

Animal experimental protocols were in consistent with
the Care and Use of Laboratory Animals Guide and
approved by the Institutional Animal Care & Use Committee of Thomas Jefferson University (No. 01159). For
establishing human ovarian cancer xenograft model in
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nude mice, 1 × 106 A2780 cells suspended in 100 μl PBS
with 50% Phenol Red-free Matrigel (Corning, NY, USA)
were injected into flanks of 6-week-old female NCr nude
mice (Taconic, US). Tail vein injections of Exo-con or
Exo-NAC (100 μg in 100 μl PBS) were performed every
3 days. Tumors were measured with calipers and tumor
volume was calculated with formula (width)2 × length/2.
Mice were sacrificed 21 days after cell inoculation or
the maximum tumor dimension reached 2.0 cm before
21 days.
For establishing immunocompetent mouse ovarian
cancer model in C57BL/6 mice (Taconic), 8 × 106 ID8miR-con or ID8–155 mouse ovarian cancer tumor cells
were inoculated intraperitoneally (i.p.) into C57/BL6
mice. Exosomes derived from ID8-miR-con (Exo-miRcon) or ID8-miR-155 (Exo-miR-155) tumor cells were
prepared and injected via tail vein every 3 days. Starting
at 60 days after tumor inoculation, mice were given IgG
isotype control or anti-PDL1 antibodies at 200 μg/mouse
every 3 days via intraperitoneal injection (IP). Mice were
sacrificed when weight gain more than 30% and/or more
than 40% waist circumference. Ascites, tumor nodules,
spleens, and blood samples were collected and processed
for further analysis.
Statistical analysis

Data are shown as means ± SD. All experiments were
repeated at least in triplicate. Statistical analysis were
performed by Graph-Pad Prism software (Graph-Pad
Software Inc., La Jolla, CA, USA). Differences between
two groups were calculated using the unpaired two-tailed
Student’s t-test. Statistical analyses of three or more
groups were compared using one-way analysis of variance (ANOVA). Cumulative probabilities of overall survival were computed with the Kaplan−Meier analysis
and comparisons between groups were analyzed using
the log-rank test. P < 0.05 was considered statistically
significant.

Results
ROS alter tumor exosomal miRNA signatures
with miR‑155‑5p being the most downregulated miRNA

We and others have shown that ROS alter the expression of miRNAs by regulating miRNA synthesis, transcription, and epigenetic modification [14, 15]. To
determine whether ROS influence the TME through
tumor exosomal miRNAs, we treated ovarian cancer
A2780 cells with or without H2O2, and purified A2780derived exosomes characterized by positive exosomal
markers CD63 and CD81, and a negative exosomal
marker calnexin (Fig. 1A). The exosome size distribution was determined by nanoparticle tracking analysis
(NTA) (Fig. 1B). The transmission electron microscope
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Fig. 1 ROS alter exosomal miRNA signatures while miR-155-5p being the most downregulated miRNA. A. Exosomes were isolated from A2780
cells by ultracentrifugation. Exosomes (Exo) and total cell lysate (TCL) were analyzed by immunoblotting for CD63, CD81 and Calnexin. B. Exosomes
isolated from A2780 cells were analyzed by nanoparticle tracking analysis (NTA). C-E. A2780 cells were treated with or without H
 2O2 at 100 μM for
4 h. 100 ng of exosomal RNAs were used as input for Nanostring nCounter miRNA analysis. Three biological replicates were used. The heatmap
of exosome miRNAs profile (C), the volcano plot (D), and the fold changes of representative differentially expressed exosomal miRNAs in treated
cells vs. control cells are shown (E). F. The expression levels of cellular and exosomal miR-155-5p were determined in A2780 cells treated with H
 2O2
(100 μM, 4 h). G-H The expression levels of cellular and exosomal miR-155-5p were determined in A2780, SKOV3, and Ovcar-3 cells treated with NAC
(10 mM, 4 h). \I. The expression levels of cellular miR-155-5p were determined in A2780 cells treated with catalase-PEG (250 U/ml, 4 h) or rotenone
(2.5 μM, 4 h). J. miR-155-5p expression was detected in human ovarian carcinoma tissue microarray (normal N = 40, ovarian cancer N = 160) by
in situ hybridization using double DIG-labeled miRCURY LNA miRNA detection probes (red). Data are representative of 3 independent experiments.
Data = Mean ± SD. *p < 0.05, **p < 0.01
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Fig. 2 NAC-derived tumor exosomes increase miR-155-5p level in macrophages. A. THP-1 cells were treated with PMA at 100 nM for 24 h. The
macrophage markers CD163 and CD206 were assessed by immunoblotting. B. Exosomes isolated from A2780 cells was labeled using lipophilic
tracer DiR before being incubated with macrophages for 24 h. Cellular uptake of exosomes were examined by confocal microscopy. Macrophage
nuclei were labeled with DAPI and actin cytoskeleton was labeled with Phalloidin. C. MΦ was treated with A2780-derived exosomes (Exo-con)
and NAC-treated A2780-derived exosomes (Exo-NAC) at 100 μg/ml for 48 h. MiR-155-5p level was detected by RT-qPCR. D-G. Macrophages were
transfected with DICER siRNASmartpool (si Dicer) or negative siRNA control (si Cont) for 24 h followed by Exo-con and Exo-NAC treatment for
another 48 h. (D) Dicer mRNA expressions in macrophages were determined. (E) miR-145 and miR-9 expression levels were set as controls. (F,
G) Pre-miR-155 and miR-155-5p levels were measured by qPCR in macrophages with treatments as indicated. Data are representative of three
independent experiments. Data = Mean ± SD. *p < 0.05, **p < 0.01

image revealed intact vesicles around 100 nm (right
panel) in diameter (Fig. S1A). The exosomal miRNA
profile determined by a NanoString nCounter microarray analysis, showed a number of differentially
expressed miRNAs in H
 2O2-treated cells compared
with those in control cells (Fig. 1C-E). Notably, exosomal miR-155-5p emerged as the most strongly downregulated miRNA in H
 2O2-treated A2780 cells. We
validated the microarray result by RT-qPCR by showing that H2O2 decreased both cellular miR-155-5p and
exo-miR-155-5p expression levels (Fig. 1F). N-acetylL-cysteine (NAC) is a non-selective antioxidant which
can similarly inhibit intracellular ROS as other scavengers such as catalase and rotenone. We observed ROS
reductions in A2780 cells treated with NAC, catalasePEG, and mitochondria complex I inhibitor rotenone
with flow cytometry and fluorescent microscope using
different dyes based on the ROS species (Fig.S1B, C).
We then treated three ovarian cancer cell lines with
NAC. As expected, both cellular miR-155-5p and exosomal miR-155-5p levels were decreased in ovarian
cancer cells (Fig. 1G, H). To confirm that miR-155-5p
is a bona fide ROS-sensitive miRNA, we also treated
A2780 cells with catalase-PEG and rotenone. The

expression levels of miR-155-5p were significantly
increased with the ROS inhibitors (Fig. 1I).
miR-155-5p has been considered as an oncomiR in
lymphoma, pancreatic, and oral squamous cell carcinoma cancers, and an oncosuppressor-miR in melanoma
and colon cancer, as well as ovarian cancer [16–20]. To
examine the abundance of miR-155-5p in ovarian cancer,
we analyzed human ovarian carcinoma tissue microarray
(TMA) for miR-155-5p expression by fluorescence in situ
hybridization (FISH). Compared with normal ovarian tissues, the expression levels of miR-155-5p in ovarian cancer tissues were significantly lower (Fig. 1J), indicating
a likely tumor suppressor role of miR-155-5p in ovarian
cancer.
NAC‑derived tumor exosomes increase miR‑155‑5p levels
in macrophages

TAMs are major types of stromal cells within the ovarian cancer TME. To determine whether tumor exosomes
can be taken up by macrophages, we first allowed differentiation of THP-1 cells into CD206+ and CD163+ macrophages with phorbol 12-myristate 13-acetate (PMA)
treatment (Fig. 2A). We then treated macrophages with
DiR-labeled exosomes for 24 h. Exosomes were detectable in the cytosol of macrophages as visualized by
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confocal microscopy indicating these exosomes are taken
in by macrophages (Fig. 2B). To determine the impact
of tumor exosomes on macrophages, we treated macrophages (PMA-treated THP-1) with exosomes derived
from NAC-treated A2780 cells (Exo-NAC) and exosomes
derived from A2780 cells (Exo-con). The result showed
elevated expression levels of miR-155-5p in Exo-NAC
treated macrophages compared to Exo-con treated
macrophages (Fig. 2C). Moreover, to rule out the possibility that de novo expression of miR-155-5p in macrophages is the source for the increased miR-155-5p, we
knocked down Dicer in macrophages with siRNAs in
order to disrupt the formation of mature miRNAs. As
seen in Fig. 2D, the expression levels of Dicer were markedly reduced in the knockdown cells. Dicer knockdown
greatly reduced expression of miRNAs, as evidenced by
examples of miR-9 and miR-145 (Fig. 2E). Moreover,
neither tumor exosomes nor Dicer knockdown affected
pre-miR-155-5p expression levels (Fig. 2F). However,
regardless of Dicer knockdown, levels of mature miR155-5p increased with Exo-NAC treatment (Fig. 2G),
demonstrating that the increased miR-155-5p in macrophages comes from tumor exosomes. Collectively,
the results showed that inhibiting ROS in ovarian cancer cells increases the release of exo-miR-155-5p that is
taken up by macrophages, resulting in the elevation of
miR-155-5p.
Exo‑miR‑155‑5p inhibits macrophage migration and tumor
infiltration in vitro

Next, we generated an A2780 cell line stably expressing miR-155-5p (A2780-miR-155) and miR-con cell line
(A2780-miR-con). Expression levels of both cellular
miR-155-5p and exosomal miR-155-5p were significantly
higher in the A2780-miR-155 cells than in the control.
cells (Fig. S2A). To investigate if A2780-miR-155derived exosomes (Exo-miR-155) affect macrophage
migration, we performed a wound healing assay. The
gap closure rates in macrophages treated with Exo-NAC
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or Exo-miR-155-5p for 24 h were markedly slower than
their corresponding control cells. This indicates that ExoNAC and Exo-miR-155-5p inhibit macrophage motility that is critical for macrophage recruitment into the
TME (Fig. 3A). Furthermore, we examined a number of
chemokines that are known to have chemotactic properties of various leukocyte subsets (Fig. S3A). We found
CXCL10 and CCL2 were significantly decreased when
treated with Exo-NAC or Exo-miR-155 in comparison
to Exo-con or Exo-miR-con (Fig. 3B), suggesting these
chemokines may contribute to macrophage mobilization.
A high degree of TAM infiltration in tumor tissues
correlated with poor prognosis in many cancers. Next,
we investigated whether tumor exo-miR-155-5p can
reduce macrophage infiltration in vitro using a threedimensional (3D) model to recapitulate the interaction
between macrophages and ovarian cancer cells. First, we
established 3D tumor spheroids using A2780-miR-con
and A2780-miR-155 cells (Fig. 3C, S3B). A2780-miR-155
spheroids grew slower than A2780-miR-con as reflected
by spheroid diameters 10 days after seeding, suggesting a tumor suppressive role of miR-155-5p. To build a
co-culture model, A2780 cells were seeded onto nonadherent plates and were allowed to form spheroids for
4 days. Then, 20,000 CD14-positive THP-1 cells were
added to the spheroids for an additional 4 days (Fig. 3D).
Flow cytometry analysis showed the amounts of infiltrating macrophages in the A2780-miR-155 spheroids
were significantly lower than those in the A2780-miRcon spheroids (Fig. 3E). To exclude the possibility that
the decrease of macrophages was apoptotic-related, we
conducted the apoptosis assay by Annexin V and 7-AAD
staining, and found no significant change regarding the
percentages of apoptotic tumor cells and macrophages
(Fig. 3F). Then tumor cells and macrophages in the spheroids were sorted by FACS with the indicated gates followed by total RNA extraction (Fig. S3C). As expected,
the miR-155-5p level increased in macrophages when
co-cultured with A2780-miR-155 spheroids, indicating

(See figure on next page.)
Fig. 3 Exo-miR-155-5p inhibits macrophage migration and tumor infiltration. A. Macrophages were treated with Exo-con, Exo-NAC, Exo-miR-con
(exosomes isolated from A2780-miR-con cells), or Exo-miR-155 (exosomes isolated from A2780-miR-155 stable cells), respectively for 48 h. The
medium was then replaced and the cells were cultured for another 24 h after generating the scratches. Representative images are shown. B.
Chemokines expressions in macrophages treated with Exo-con/Exo-NAC or Exo-miR-con/Exo-miR-155 were determined by RT-qPCR. C. The
schematic diagram of the 3D co-culture model setup. A2780-miR-con and A2780-miR-155 stable cells were cultured to form tumor spheroid for
4 days. The same amount of macrophages were added and co-cultured for another 4 days. D. The representative images were shown after 4 days of
3D co-culture. E. The 3D co-cultures spheroids were re-suspended into single cell suspensions and analyzed by flow cytometry to determine the
amounts of A2780 cells and infiltrated macrophages. F. The percentages of apoptotic A2780 cells and macrophages after co-culture were analyzed
by flow cytometry. G-H. The CD14 positive infiltrated macrophages were isolated from 3D co-culture models using FACS. The expression levels of
miR-155-5p (G) CXCL10, and CCL2 (H) were measured by RT-qPCR. I. A2780-miR-con and A2780-miR-155 stable cells were stained with cell tracker
green before seeding onto 1% agarose concave surface for spheroid formation. Macrophages were stained by eFluor670 before adding into tumor
spheroids. Representative images were taken by confocal microscope for 3D live cell imaging at 4 x magnification. The number of A2780 and
infiltrated macrophages were analyzed as accumulative average fluorescent intensities. Green: A2780. Purple: macrophages. Data are representative
of three independent experiments. Data = Mean ± SD. *p < 0.05, **p < 0.01
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the transfer of exosomes from tumor cells (Fig. 3G). Then
we analyzed the mRNA levels of chemokines associated
with invasive phenotype in macrophages by RT-qPCR
(Fig. 3H, S3D). Compared with macrophages in A2780miR-con spheroids, the expression levels of CXCL10
and CCL2 significantly downregulated in macrophages
in A2780-miR-155 spheroids (Fig. 3H). Among all the
chemokines we detected in A2780 cells, CXCL10 and
CCL2 levels were also lower in A2780-miR-155 cells
sorted from spheroids (Fig. S3E). To observe the co-culture model in a spatiotemporal manner, we utilized cell
tracker green-labeled A2780 spheroids and eFluor670labeled infiltrating macrophages for 3D live cell imaging
using confocal microscopy. In line with the results that
we showed in Fig. 3E, fewer macrophages infiltrated into
A2780-miR-155 spheroids compared with the control as
reflected by lower fluorescent intensities (Fig. 3I, Movie.
S1, S2). Taken together, these data suggest that ROSrelated tumor exo-miR-155-5p is able to inhibit macrophage migration and infiltration.
PD‑L1 is a target of miR‑155‑5p in macrophages

PD-L1 is a putative target of miR-155-5p with two potential miR-155-5p-binding sites in its 3′-UTR regions that
are conserved in humans and mice (Fig. 4A). It was
reported that miR-155-5p negatively regulates PD-L1
protein expression by directly binding the 3′ UTR of
PD-L1 mRNA in human dermal lymphatic endothelial
cells [21]. Interestingly, another study showed that miR155 positively regulates the transcriptional activity of the
PD-L1 gene in HEK-293 T cells [22]. To investigate the
effect of miR-155-5p on PD-L1 expression levels, we cotransfected THP-1 cells with miR-cont, or miR-155-5p,
and a PD-L1 3′ UTR full-length luciferase reporter. miR152 served as positive control as it has been validated a
direct target of PD-L1, andmiR-137 was used as a negative control since it does not contain predictive binding
sites on PD-L1 3’UTR regions [23, 24]. Co-transfection
of miR-155-5p or miR-152 with the PD-L1 reporter
decreased luciferase activities while co-transfection of
miR-cont or miR-137 did not affect luciferase activities,
suggesting miR-155-5p inhibits PD-L1 expression at the
transcriptional level in THP-1 cells (Fig. 4B). Moreover,
overexpression of miR-155-5p decreased PD-L1 protein
levels with or without IFN-ɣ induction (Fig. 4C).
To determine whether tumor exosomes inhibit PD-L1
protein levels in macrophages, we treated macrophages
with Exo-miR-155 and Exo-miR-con, and found ExomiR-155 treatment decreased PD-L1 expression significantly in macrophages compared to Exo-miR-con
treatment (Fig. 4D). Immunoblotting showed that ExomiR-155 decreased IFN-γ-induced PD-L1 protein levels
in macrophages (Fig. 4E). We had shown that Exo-NAC
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treatment increased miR-155-5p in macrophages
(Fig. 2D). In line with this result, Exo-NAC effectively
suppressed PD-L1 protein levels in macrophages (Fig. 4F,
G). In 3D coculture models, the PD-L1 expression levels in macrophages that were separated from A2780miR-155 tumor spheroids were lower than those from
A2780-miR-con spheroids (Fig. 4H). We transiently
transfected a PD-L1 expressing plasmid or a control vector in macrophages for 48 h, then added into the tumor
spheroids. We observed that overexpression of PD-L1
reversed the inhibition of miR-155-5p on macrophage
tumor infiltration (Fig. 4I). These results suggest the
uptake of tumor exo-155-5p reduced macrophage infiltration through PD-L1.
NAC‑derived tumor exosomes inhibit tumor growth
and macrophage infiltration in nude mice

Tumor xenografts were generated by A2780 cells by
injection onto the flanks of female NCr nude mice. At
3 days after the implantation, Exo-con or Exo-NAC
(100 μg in 100 μl PBS) was intravenously administered
via the tail vein every 3 days, and tumor growth was
monitored 3 times a week for 21 days (Fig. 5A). The mice
treated with Exo-NAC grew smaller tumors compared
to the mice treated with Exo-con (Fig. 5B, C). FACS was
used to isolate macrophages from tumors (Fig. S4A) and
spleens (Fig. S4B) in single cell suspensions with the
indicated gates. The amount of tumor infiltrating macrophages in mice treated with Exo-NAC was significantly
lower than in mice treated with Exo-con (Fig. 5D). The
mouse macrophage marker F4/80 was also stained by
IHC in tumor tissues (Fig. 5E), which showed similar
results as illustrated in flow cytometry (Fig. 5D). The
miR-155-5p expression level was significantly higher in
macrophages isolated from tumors and spleens in mice
treated with Exo-NAC (Fig. 5F), indicating miR-155-5p
might be a major functional molecule in NAC-treated
exosome cargo to downregulate PD-L1. As expected, the
expression levels of PD-L1 in tumor tissues and tumor
macrophages were significantly lower in mice treated
with Exo-NAC (Fig. 5G, H). Collectively, these findings
suggest that NAC-derived tumor exosomes are able to
inhibit xenograft tumor growth and macrophage infiltration, in which the Exo-miR-155-5p/PD-L1 pathway
might play a pivotal role.
Macrophages treated with tumor exo‑NAC
or exo‑miR‑155‑5p promote cytotoxic T cells activation
through PD‑L1 in vitro

Accumulating evidence suggest that tumor-associated
macrophage infiltration can promote tumor progression
by impairing the immune responses of cytotoxic C
 D8+
T cells in the tumor microenvironment [25]. We asked
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Fig. 4 PD-L1 is a target of miR-155-5p in macrophages. A. Target Scan predicted 2 potential binding sites of miR-155-5p on PD-L1 3′-UTR. B. THP-1
cells were co-transfected with PD-L1 full-length 3’UTR plasmid and miR-cont, miR-155, miR-152 or miR-137. Luciferase activities were normalized by
the Renilla control’s luciferase activity. miR-152 was set as a positive control, and miR-137 as a negative control. C. Macrophages were transfected
with miRNA mimic control (miR-con) or miR-155-5p mimic (miR-155) for 48 h. PD-L1 expression was determined by immunoblotting. D-E.
Macrophages pre-treated with IFN-γ (100 ng/ml, 24 h) were treated with Exo-miR-con or Exo-miR-155 at 100 μg/ml for 48 h. PD-L1 expression levels
were determined by flow cytometry and immunoblotting. F-G. Macrophages pre-treated with IFN-γ (100 ng/ml, 24 h) were treated with Exo-con
and Exo-NAC at 100 μg/ml for 48 h. PD-L1 expressions were detected by flow cytometry and immunoblotting. Mean Fluorescence Intensity (MFI)
was statistically analyzed. H. PD-L1 expression levels in macrophages in A2780-miR-con spheroids and A2780-miR-155 spheroids as described
in Fig. 4 were determined by flow cytometry. I. Macrophages were transiently transfected with PD-L1 or vector for 48 h before adding to the 3D
tumor spheroids. The number of tumor infiltrating macrophages was determined by flow cytometry. Data are representative of 3 independent
experiments. *p < 0.05, **p < 0.01
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Fig. 5 NAC-derived tumor exosomes reduce tumor growth and macrophage infiltration in nude mice. A. A2780 cells were injected into the flanks
of 6-week-old female BALB/c nude mice. Tail vein injections of Exo-con or Exo-NAC (100 μg in 100 μl PBS) were performed every 3 days. Mice were
terminated 21 days after the cell inoculation or the diameter of tumor reached 2.0 cm. B-C. Tumor growth curve and tumor weights are shown.
N = 10 mice /group. D. The proportions of macrophages in tumors were measured by cell sorting (n = 5). E. Tumor tissues were sectioned and
analyzed by IHC for macrophage marker F4/80 expression. Representative images of HE staining and IHC are shown (n = 5). Scale bar =200 μm. F.
The miR-155-5p levels in tumor macrophages and splenic macrophages were measured by RT-qRCR (n = 4–5). G. Tumor tissues were sectioned
and analyzed by IHC for PD-L1 expression. Representative images of IHC are shown (n = 5). Scale bar = 200 μm. H. Tumor macrophages and splenic
macrophages were sorted and analyzed by flow cytometry for PD-L1 expression (n = 5). Isotype control: IgG. Data = Mean ± SD. *p < 0.05, **p < 0.01

whether macrophages treated with the exosomes impact
T cell functions. To address this question, we isolated
CD3+ T cells from human PMBC and activated T.
cells with CD3, CD28, and IL-2. Next, we co-cultured
activated T cells with macrophages pre-treated with
Exo-NAC, Exo-miR-155, or their respective controls for
24 h. The T cell function was evaluated by the percentage of cytotoxic CD8+ T cells (Fig. S5A) as well as the
apoptosis of T cells using flow cytometry (Fig. S5B).
Compared to the controls, Exo-NAC and Exo-miR-155
treated-macrophages significantly increased the C
 D8+
T cell proportion (Fig. 6A). The apoptosis rate of T cells
after co-culture with exosome-treated macrophages was

also examined by Annexin V/7-AAD staining. The results
showed the percentage of apoptotic CD3+ T cells was
significantly reduced after co-culturing with Exo-NAC
and Exo-miR-155 treated macrophages compared with
their respective controls (Fig. 6B).
Next, we isolated CD8+ T cells from the co-culture
system to analyze the intracellular production of tumor
necrosis factor alpha (TNF-α), gamma interferon (IFNγ) and interleukin-2 (IL-2). The mRNA levels of these
cytokines in CD8+ T cells were significantly increased
after being co-cultured with Exo-NAC- and Exo-miR155-treated macrophages (Fig. 6C). To determine
whether CD3+ T cell activation is mediated by PD-L1, we
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Fig. 6 Exo-155-5p-treated macrophages activate cytotoxic T cells. A-B. Macrophages were pretreated with Exo-con, Exo-NAC, Exo-miR-con or
Exo-miR-155 at 100 μg/ml for 48 h followed by co-cultured with activated T cells for another 48 h. Flow cytometry was performed to analyze CD8+
T cells proportion (A) and CD3+ T cell apoptosis (B). C. CD3+ T cells were sorted from the co-culture systems using FACS. Total RNA was extracted
and the mRNA levels of chemokines were measured by RT-qPCR. D. Macrophages were transfected with PD-L1 or vector for 48 h before the
Exo-miR-155 treatment followed by the co-culture with T cells for another 48 h. C
 D4+ and CD8+ T cells proportions were determined by flow
cytometry. Data are representative of 3 independent experiments. Data = Mean ± SD. *p < 0.05, **p < 0.01. Abbreviations: Exo-con: Exo-con-treated
macrophages + T cells; Exo-NAC: Exo-NAC-treated macrophages + T cells; Exo-miR-con: Exo-miR-con-treated macrophages + T cells; Exo-miR-155:
Exo-miR-155-treated macrophages + T cells; Exo-miR-155 + PD-L1: macrophages overexpressed PD-L1 with Exo-miR-155 treatment + T cells

transfected PD-L1 in macrophages before co-culturing
with the T cells. We observed that PD-L1 overexpression effectively reversed an exo-miR-155-5p-mediated

increase of CD8+ T cell (Fig. 6D), suggesting that ExomiR-155-5p-treated macrophages can activate T cell
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Fig. 7 Exo-miR-155-5p suppresses tumor growth in immunocompetent mice. A. DiR-labeled exosomes (100 μg) were intravenously injected
into C57/BL6 mice. The photos of liver, lung, spleen and heart were taken at 2, 12, and 24 h after the injection by In Vivo Imaging System (IVIS)
spectrum. B. The schematic diagram of mice study design. C. Representative images of ascites and tumor nodes dissemination in peritoneal
cavity. D. Kaplan-Meier survival curves among groups. Mice were terminated when they gained more than 40% waist circumference and/or 30%
body weight or showed any signs of cachexia. Log rank P (Exo-miR-con+anti-IgG vs. Exo-miR-con+anti-PDL1) = 0.0132; P (Exo-miR-con+anti-IgG
vs. Exo-miR-155 + anti- IgG) = 0.0002; P (Exo-miR-con+anti-PDL1 vs. Exo-miR-155 + anti-PDL1) = 0.0213; P (Exo-miR-155 + anti-IgG vs.
Exo-miR-155 + anti-PDL1) = 0.1657. E. Waist circumference was measured weekly as an indicator of ascites accumulation (tumor progression). F.
Individual waist measurements of mice over time (n = 9 in ID8-miR-con group, n = 10 in ID8-miR-155 group)

functions by increasing CD8+ T cell ratio and decreasing
T-cell apoptosis mainly through PD-L1 downregulation.
Tumor exo‑miR‑155‑5p inhibits tumor growth
and macrophage infiltration and activates CD8 positive T
cells in immune‑competent mice

Next, we asked whether tumor exo-miR-155-5p could
suppress tumor progression and activate the anti-tumor
immune response in immune-competent mice. First,
we examined the exosome distribution after in vivo
delivery in C57BL/6 mice. The exosomes were detectable in the liver, spleen, and lung after 24 h (Fig. 7A).
Next, we generated a murine ovarian cancer cell line
ID8 stably expressing miR-155-5p (ID8-miR-155) and
miR-con cell line (ID8-miR-con). The expression levels
of both cellular miR-155-5p and exosomal miR-155-5p
in ID8-miR-155 cells were 3-fold higher than those
in control cells (Fig. S2B). We then established tumor
models by intraperitoneal injection of ID8-miR-con or
ID8-miR-155 cells into C57BL/6 mice. Exosomes from
ID8-miR-con cells (Exo-miR-con) or exosomes from

ID8-miR-155 cells (Exo-miR-155) were administered
every 3 days, with anti-PD-L1 or anti-IgG antibodies
administered starting at 60 days after tumor inoculation (Fig. 7B). Because ascites accumulation causes
waist gain that can be used as an index of tumor progression in ID8 model [26], we monitored the tumor
progression by measuring weight and waist circumference. Mice were euthanized when they gained more
than 30% body weight and/or more than 40% waist
circumference or showed any signs of cachexia or distress [26]. Mice in the control group developed visible
ascites starting around 70 days after tumor implantation (Fig. 7C, left), and multiple tumor nodules were
disseminated in the peritoneal cavity, including parietal and visceral surfaces (Fig. 7C, right). Delivery of
Exo-miR-155 repressed tumor growth as evidenced by
prolonged survival and delayed waist gain (Fig. 7D, E,
F). Notably, Exo-miR-155 was more potent than antiPD-L1 antibody treatment for inhibiting tumor growth.
In addition, the combination of exo-miR-155-5p with
anti-PD-L1 did not further improve the survival of
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the mice compared with exo-miR-155-5p treatment
alone. These results indicated that additional factors
are involved in miR-155-5p-mediated tumor suppression, and that the effects of anti-PD-L1 antibody and
Exo-miR-155-5p on tumor growth may be repetitive instead of additive. Having demonstrated that
tumor exo-miR-155-5p inhibited macrophage infiltration in vitro, we further investigated its effects on
macrophage infiltration in vivo. Higher levels of miR155-5p were found in exosomes isolated from ascites
and serum in mice treated with Exo-miR-155, indicating a successful in vivo delivery of exo-miR-155-5p
(Fig. 8A). The expression of macrophages marker F4/80
was lower in tumors in the Exo-miR-155-treated group
by IHC (Fig. 8B). The proportion of macrophages in
tumor samples was analyzed by FACS. The mice treated
with either anti-PD-L1 antibody or exo-miR-155-5p
had far fewer TAMs compared with the control mice
(Fig. 8C). Moreover, the expression levels of miR155-5p in ascites macrophages and spleen macrophages
were elevated in the Exo-miR-155 group, suggesting
tumor exo-miR-155-5p was uptaken by macrophages
(Fig. 8D). Next, we examined PD-L1 expression in macrophages from ascites and tumors. Consistent with
the findings obtained in nude mice, the expression of
PD-L1 in ascites, and tumor macrophages were significantly lower in mice treated with Exo-miR-155 than
in mice treated with Exo-miR-con (Fig. 8E). Similarly,
the expression of PD-L1 in tumor tissue samples in
the Exo-miR-155 group were generally downregulated
determined by immunoblotting and IHC (Fig. 8F, G).
Lastly, we examined the effects of tumor exo-155-5p
on T cell function in vivo. The percentages of C D8+ T
cells from ascites and spleen in mice from Exo-miR-155
group were significantly increased compared with those
in control groups (Fig. 8H). As expected, the anti-PDL1 antibody increased the percentage of C
 D8+ T cells.
Notably, adding anti-PD-L1 to Exo-miR-155 had no
synergistic or additive effect on C D8+ T cells compared to Exo-miR-155 alone. Collectively, these in vivo
findings indicate that exo-miR-155-5p inhibits tumor
progression and prevent formation of the suppressive
tumor microenvironment by reducing macrophage
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infiltration and subsequently activating T cell antitumor immune responses in ovarian cancer.

Discussion
Here we provide evidence that the redox status of tumor
cells serves as a critical regulator of the microenvironment in the control of immunologic mechanisms
involved in their response to therapy. Compared with
normal cells, cancer cells exhibit an increased level of
intrinsic reactive oxygen stress because of mitochondrial dysfunction and metabolic alteration, reflecting a
disorder of redox homeostasis [15, 27, 28]. Recent studies have shown that ROS promote tumor immune escape
by creating an immunosuppressive tumor microenvironment [29, 30]. For example, excessive ROS production
can reduce the infiltration of lymphocytes and facilitate
recruitment and accumulation of regulatory T-cells and
M2-like tumor-associated macrophages [30, 31]. A recent
study showed that the inhibition of NADPH oxidase
subunit NOX4 potentiates immunotherapy by preventing the formation of immunosuppressive phenotypes of
cancer-associated fibroblast [32]. Consistent with this
finding, we found inhibition of ROS by NAC was able to
reprogram macrophages with tumor exosomes to suppress ovarian cancer development. We and other groups
have shown that ROS-sensitive microRNAs contribute
pivotally with respect to how cancer cells respond to
ROS [14, 15, 33]. In this study, we identified exosomal
miR-155-5p as a major downstream effector of ROS that
mediates tumor immune responses. Given the dual roles
of ROS in cancer development, the use of antioxidants
in cancer treatment has had limited or even unexpected
effects. A study showed that NAC and vitamin E accelerated lung cancer progression in a mouse model [34]. It is
plausible that targeting downstream ROS-sensitive miRNAs, such as miR-155-5p, may provide a more specific
approach to manipulation of ROS effects.
A key question in miRNA research is how their
expression is regulated under specific contexts. Studies
from different groups show that ROS are able to influence microRNAs through altering miRNA biogenesis,
transcription factors, and epigenetic modulation [15].
Our prior study showed that endogenous ROS inhibit

(See figure on next page.)
Fig. 8 Exo-miR-155-5p activates CD8 positive T cells in vivo. A. Exosomes in ascites and serum were isolated and purified. The expression of
exo-miR-155-5p was determined by RT-qPCR (n = 4–7). B. The expression of macrophage marker F4/80 was analyzed by IHC in tumor tissues.
Representative images of HE staining and IHC are shown (n = 5). Scale bar = 200 μm. C. The proportions of macrophages in tumors were measured
by cell sorting (n = 3–4). D. Macrophages were isolated from ascites and spleen using FACS followed by miR-155-5p detection with RT-qPCR
(n = 3–6). E. Flow cytometry was performed to determine the PD-L1 expression in macrophages from ascites (n = 6), spleen (n = 4–5), and
tumor tissues (n = 4–5). Mean Fluorescence Intensity (MFI) was statistically analyzed. F. The PD-L1 expressions were analyzed in tumor tissues by
immunoblotting (n = 4/group). The densitometry of bands was quantified with image J. G. The expression PD-L1 in tumor tissue was determined
by IHC. Representative images IHC are shown (n = 5). Scale bar = 200 μm. H. CD3+ CD8+ T cell subsets in ascites and spleen were analyzed by flow
cytometry. The percentages of CD8+ cells were indicated (n = 6–7). Data = Mean ± SD. *p < 0.05, **p < 0.01
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miR-199a and miR-125b genes expression through DNA
hypermethylation in ovarian cancer cells [35]. However,
the mechanisms by which ROS inhibit cellular and exosomal miR-155-5p levels in ovarian cancer cells are not
clear. It is known that the transcription factor nuclear
factor-κB (NF-κB), a redox-sensitive factor, can transactivate miR-155-5p gene expression [15]. Some studies
have suggested that TNF-α-induced ROS accumulation
decreases NF-κB expression and the level of its target
miR-155-5p [36]. However, other groups argued that
the rise of intracellular ROS levels, induced by TNF or
IL-1, can up-regulate JNK-mediated NF-κB activation
[37]. ROS production exerts opposing effects on NF-κB,
inducing activation in the cytoplasm and inactivation in
the nucleus [38]. To add complexity, reciprocal regulations exist between ROS and NF-κB signaling [39, 40].
Whether and how ROS regulate miR-155-5p through
NF-κB remains unclear and is a topic worthy of further
investigation.
TAMs represent the most abundant infiltrating
immune cells in the peritoneal tumor microenvironment to influence ovarian cancer initiation, growth,
and metastasis [41]. A meta-analysis showed that a high
density of 
CD163+ TAMs infiltration was associated
with poor prognosis in ovarian cancer [42]. It has been
reported that exosomes derived from ovarian cancer
cells are capable of educating macrophages to obtain
the tumor-promoting M2 phenotype [43, 44]. We found
tumor exosomal miR-155-5p inhibited tumor growth
through macrophage infiltration inhibition and T cell
activation. PD-L1 is an inhibitory checkpoint molecule
known for its role in negative regulation of cytokine production and T cell function. PD-L1 is widely expressed in
tumor cells, tumor infiltrating lymphocytes, and tumor
stromal cells, especially tumor-associated CD68+ macrophages in ovarian cancer [45]. Expression of PD-L1 on
dendritic cells and macrophages in ovarian cancer and
melanoma patients correlated with the efficacy of treatment with either anti-PD-1 alone or in combination
with anti-CTLA-4 [46]. However, it remains elusive how
PD-L1 expression is upregulated in macrophages. Studies
have shown that miR-155-5p inhibits PD-L1 expression
by binding the 3′ UTR of PD-L1 mRNA [21, 22]. In this
study, we found PD-L1 expression was lower in tumor
and spleen macrophages in mice treated with Exo-miR155-5p. Moreover, overexpression of PD-L1 reversed
tumor exosomal miR-155-5p-induced C
 D8+ T cell proliferation, suggesting PD-L1 contributes to miR-155-5pmediated anti-tumor immune response.
To date, the blockade of immune checkpoints in ovarian cancer has produced mixed results in preclinical setting and clinical trials [47, 48]. Krempski et al. reported
that PD-1 antibody alone facilitated tumor regression
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and T cell function and activation while many others
found a lack of response [49, 50]. In this study, we found
PD-L1 antibody alone delayed tumor progression and
ascites formation. Notably, exo-miR-155-5p inhibited
tumor growth more potently than PD-L1 antibody, and
the combination of the two agents failed to achieve better efficacy than exo-miR-155-5p alone. This indicates
that PD-L1 inhibition by miR-155-5p may not entirely
account for the immunosuppressive effects observed,
suggesting that other pathways also contribute to miR155-5p-mediated anti-tumor responses.
miR-155-5p has been recognized as a pro-inflammatory factor that can enhance the production of IL-1β,
IL-6, IL-8, and TNF [51, 52]. It has been implicated
in innate and adaptive anti-tumor immune response.
Deletion of miR-155-5p reduces the capability of C
 D8+
cytotoxic T cells to respond to viral infection or tumor
development [53], and aberrant expression of miR1555p correlates with inflammation through targeting and
degrading SHIP1 and WEE1 genes involved in inflammation [54, 55]. In addition to PD-L1, overexpression of miR-155-5p can reprogram tumor-associated
macrophages to pro-inflammatory, antitumor macrophages, possibly by targeting C/EBP-ß and NF-ĸB and
thus suppressing their signaling cascades [33, 56]. Our
results showed that tumor exo-NAC or exo-miR-155-5p
decreases CXCL10 and CCL2 expression levels in macrophages. Co-culture with macrophages treated with
tumor exo-NAC or exo-miR-155-5p increased TNF-α,
IFN-ɣ, and IL-2 levels in T cells. It remains to be investigated whether miR-155-5p regulate the chemokines
directly or indirectly through PD-L1 or other pathways.
Notably, the direct role of miR-155-5p in ovarian cancer
cells is not clear yet. There is no significant change of cell
proliferation in A2780-miRcont cells vs. A2780-miR155-5p cells by MTT assay (72 h, data not shown). However, when co-cultured with macrophages in a 3D model,
A2780-miR-155 cells in the spheroids grew slower than
control cells starting at day 7 (Fig.S3B). In line with the
mice study, we consider that miR-155-5p inhibits tumor
growth mainly through the tumor microenvironment
and adaptive immune response. However, this warrants
further investigation.

Conclusions
We demonstrated a mechanism by which ovarian cancer cells inherently with high level of ROS decreases
the amount of tumor exo-miR-155-5p that is taken
up by macrophages to create an immunosuppressive microenvironment characterized by upregulation of PD-L1 and other immunosuppressive factors
(Fig. 9). Understanding of the negative impact of ROS
on the tumor immune response will improve current
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Fig. 9 Graphic abstract. High level of ROS in cancer cells decrease tumor exosomal miR-155-5p that is taken up by macrophages to create an
immunosuppressive microenvironment by upregulation of PD-L1 and other immunosuppressive factors that foster ovarian cancer development.
Increase of tumor exo-miR-155 prevents ROS-mediated suppressive tumor immune response in ovarian cancer

therapeutic strategies. Targeting miR-155-5p can be
an alternative approach to prevent formation of ROSmediated immunosuppressive TME. So far, the application of microRNAs in humans is hindered by lack of
approaches to achieve high efficiency and safety concern for in vivo delivery of microRNA mimic or antimiR inhibitor. As exosomes may act as a promising and
innovative nanocarrier for drug delivery characterized
by their lower immunogenicity, but higher biocompatibility and greater circulation stability [57], the development of an exosome-mimicking liposome (EML)
formulation of miR-155-5p that mimics the exosomes
in which it is enclosed may have potential to provide
significant clinical benefit to ovarian cancer patients.
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